PharmaCielo has appointed Mr. Henning von Koss to the new role of President, overseeing all day-to-day operations and project development with immediate effect. Mr. von Koss will remain on the board of directors of PharmaCielo.
"Mr. von Koss’s career spans over 30 years’ international experience in various sectors and includes senior executive roles with global chemical /pharmaceutical giant Bayer, large health managed organizations as well as manufacturing and fashion retail companies," the team with the company explains. "Mr. von Koss has spent his career managing operations primarily in Latin America and Europe, with experience in several countries, including Brazil, Colombia, Venezuela, Germany and Poland."
“On our Q4 conference call last week I mentioned that we were in the final stages of adding an experienced senior executive to the team, and I am very pleased to announce the appointment of Henning von Koss to the role of President, effective today,” commented David Attard, CEO. “With a robust agenda ahead for 2020, we identified the need for a proven leader with deep experience in Latin America and Europe, specifically to ensure our processing and extraction capabilities come online in an efficient manner, to assist with our sales and product strategy particularly as we grow in Europe and to ensure we are ready to scale further in 2021. Henning is a known quantity, having made several key contributions to the Company’s development as a member of the board of directors and as an individual, I have heavily relied on since becoming CEO. I have been consistently impressed by his strategic contributions, influenced by extensive Latin American operational experience in the health care sector and product manufacturing and I know he will help us ensure that we are on track to deliver results this year while preparing for further growth in 2021 and beyond.”
Mr. von Koss stated, “I am grateful for the opportunity to join PharmaCielo’s executive team and support David in this endeavour. Our tremendous agricultural cost advantage, coupled with our extraction and processing capabilities, position us as the ideal long-term supplier to the industry. Recently, in a challenging environment PharmaCielo successfully closed an important capital raise. Now our priorities are very clear, together with the executive team, we must accelerate the creation of a network of global B2B customers who will benefit from the quality of our products and potentially generate revenue for the Company, while quickly and efficiently accelerating our production output to match.”